Ajai Chari, MD

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.